Form 4: Amarin Director Paul Cohen Receives Stock Options and Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Director Paul Cohen received stock options for 179,795 ordinary shares and 50,287 restricted stock units (RSUs) following Amarin's annual general meeting.

Summary

  • Paul Cohen, a director of Amarin, received stock options and restricted stock units (RSUs) on April 18, 2024.
  • The stock options are for 179,795 ordinary shares with an exercise price of $0.87.
  • These options vest over three years, with 33% vesting on the first anniversary and the remainder vesting quarterly over the subsequent two years.
  • Cohen also received 50,287 RSUs, which vest in three equal installments on April 18, 2025, April 18, 2026, and April 18, 2027.
  • Each RSU represents a contingent right to receive one ordinary share or cash at Amarin's discretion.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity is a standard practice and generally viewed favorably as it aligns management interests with shareholders.

Positives

  • The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
  • The vesting schedules encourage long-term commitment and performance.

Future Outlook

NA

Industry Context

This type of equity grant is a common practice for incentivizing and retaining key personnel, aligning their interests with the long-term success of the company. It's a standard component of executive compensation packages in the pharmaceutical industry.

Comparison to Industry Standards

  • Equity grants to directors are a common practice in publicly traded companies, particularly in the pharmaceutical sector.
  • Companies like Pfizer, Johnson & Johnson, and Novartis also use stock options and RSUs as part of their director compensation packages.
  • The vesting schedules are fairly standard, with many companies using three-year vesting periods for both stock options and RSUs.

Stakeholder Impact

  • Shareholders may view the equity grants positively as they align the director's interests with the company's performance.
  • The director is incentivized to contribute to the long-term success of the company.

Key Dates

DateDescription
04/18/2024Date of transaction: Grant of stock options and RSUs following the annual general meeting.
04/18/2025First vesting date for 33% of the stock options and first vesting date for RSUs.
04/18/2026Second vesting date for RSUs.
04/18/2027Final vesting date for RSUs.
04/18/2034Expiration date for the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.